Literature DB >> 26847085

Suppression of c‑FLIPL promotes JNK activation in malignant melanoma cells.

Fen Tian1, Yange Hu1, Xixi Sun1, Gaihui Lu1, Yan Li2, Jing Yang2, Juan Tao2.   

Abstract

The up‑regulation of cellular Fas‑associated death domain‑like interleukin‑1β‑converting enzyme (FLICE)‑like inhibitory protein (c‑FLIP) has been reported in various tumor types, and has been previously shown to be associated with the clinicopathological features of melanoma. To assess its potential role in cancer therapy, the present study evaluated the effects of short hairpin (sh)RNAs of different c‑FLIP isoforms on cellular proliferation and c‑Jun N‑terminal kinase (JNK) signaling. Human c‑FLIP shRNA plasmids were constructed and transfected into the A875 melanoma cell line. It was observed that c‑FLIP shRNA exhibited strong inhibitory effects against the levels of phosphorylated‑JNK and inhibited cellular proliferation in A875 cells. Thus, this indicated that c‑FLIP long form shRNA serves a specific inhibitory role in cellular proliferation through inducing the activation of the JNK pathway in A875 cells. The present study provided insight into the development of RNAi based therapies for melanoma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26847085     DOI: 10.3892/mmr.2016.4856

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  2 in total

1.  Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells.

Authors:  Gianluca Carnevale; Guido Carpino; Vincenzo Cardinale; Alessandra Pisciotta; Massimo Riccio; Laura Bertoni; Lara Gibellini; Sara De Biasi; Lorenzo Nevi; Daniele Costantini; Diletta Overi; Andrea Cossarizza; Anto de Pol; Eugenio Gaudio; Domenico Alvaro
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

Review 2.  The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer.

Authors:  Manel B Hammouda; Amy E Ford; Yuan Liu; Jennifer Y Zhang
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.